CorMedix announced the acceptance of the final results of their observational post-marketing study of Neutrolin for publication in the peer-reviewed European Journal of Clinical Microbiology and Infectious Diseases.

CorMedix (NYSE:CRMD) announced the acceptance of the final results of their observational post-marketing study of Neutrolin for publication in the peer-reviewed European Journal of Clinical Microbiology and Infectious Diseases.
As quoted in the press release:

Neutrolin is CorMedix’s lead product in Phase 3 development in the U.S. for preventing catheter-related bloodstream infections (CRBSI) in patients undergoing hemodialysis for end stage renal disease. The product is approved for use in the EU under an existing CE Mark.
The article, titled, “Post-Marketing Experience with Neutrolin (taurolidine, heparin, calcium citrate) Catheter Lock Solution in Hemodialysis Patients,” describes the final results of CorMedix’s Neutrolin Use Monitoring Program (NUMP). This observational study gathered data from 20 clinical sites in Germany and compared the experience of 201 patients using the product over more than 47,000 catheter days from January 2014 through September 2016 to historical rates of CRBSI and thrombosis. Now accepted, the article is expected to be published by the journal in the coming weeks, links to which will be made available on CorMedix’s website.

Click here to read the full press release.

Source: www.accesswire.com

catheter ce cormedix disease eu germany infectious diseases patients renal disease Pharmaceutical Investing